Abstract
Purpose
The physiological importance of the human ATP-binding cassette (ABC) transporter ABCG2 has been recognized with regard to porphyrin-mediated photosensitivity. Functional impairment owing to inhibition of ABCG2 by drugs or its genetic polymorphisms may lead to the disruption of porphyrin homeostasis, which in turn causes cellular toxicity.
Materials and Methods
We evaluated the impact on photosensitivity of the inhibition by cyclin-dependent kinase (CDK) inhibitors of ABCG2 function. For this purpose, we established new methods for photosensitivity assays by using Flp-In-293 cells and plasma membrane vesicles prepared from Sf9 insect cells. With the new methods, we subsequently tested CDK inhibitors, i.e., purvalanol A, WHI-P180, bohemine, roscovitine, and olomoucine.
Results
Among CDK inhibitors tested, purvalanol A was found to be the most potent inhibitor (IC50 = 3.5 μM) for ABCG2-mediated hematoporphyrin transport. At a concentration of 2.5 μM, it evoked the photosensitivity of ABCG2-expressing Flp-In-293 cells treated with pheophorbide a. WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. In contrast, the phototoxicity of bohemine, roscovitine, and olomoucine were minimal in our assay system.
Conclusions
It is suggested that the planar structure is an important factor for interactions with the active site of ABCG2. The present study provides a new approach to studying drug-induced phototoxicity in vitro.
Similar content being viewed by others
Abbreviations
- ABC:
-
ATP-binding cassette
- BCRP:
-
breast cancer resistance protein
- CDK:
-
cyclin-dependent kinase
- D-MEM:
-
Dulbecco’s modified Eagle’s medium
- EDTA:
-
ethylenediaminetetraacetic acid
- EGFR:
-
epidermal growth factor receptor
- EGTA:
-
ethyleneglycol-bis(2-aminoethyl)-N,N,N′,N′-tetracetic acid
- EKI-785:
-
N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide
- FCS:
-
fetal calf serum
- HEPES:
-
2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid
- HOMO:
-
highest occupied molecular orbital
- IC50 :
-
concentration leading to a 50%-inhibition
- K m :
-
Michaelis–Menten constant
- MXR:
-
mitoxantrone resistance
- MO:
-
molecular orbital
- QSAR:
-
quantitative structure-activity relationship
- Tris:
-
tris(hydroxymethyl)aminomethane
References
J. W. Jonker, S. Musters, M. L. Vlaming, T. Plosch, K. E. Gooijert, M. J. Hillebrand, H. Rosing, J. H. Beijnen, H. J. Verkade, and A. H. Schinkel. Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am. J. Physiol. Cell. Physiol. 292:C2204–2212 (2007). doi:10.1152/ajpcell.00359.2006.
J. W. Jonker, M. Buitelaar, E. Wagenaar, M. A. Van Der Valk, G. L. Scheffer, R. J. Scheper, T. Plosch, F. Kuipers, R. P. Elferink, H. Rosing, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99:15649–15654 (2002). doi:10.1073/pnas.202607599.
A. Tamura, M. Watanabe, H. Saito, H. Nakagawa, T. Kamachi, I. Okura, and T. Ishikawa. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 70:287–296 (2006).
A. Tamura, Y. Onishi, R. An, S. Koshiba, K. Wakabayashi, K. Hoshijima, W. Priebe, T. Yoshida, S. Kometani, T. Matsubara, K. Mikuriya, and T. Ishikawa. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokinet. 22:428–440 (2007). doi:10.2133/dmpk.22.428.
R. Allikmets, L. M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337–5339 (1998).
L. A. Doyle, W. Yang, L. V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi, and D. D. Ross. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 95:15665–15670 (1998). doi:10.1073/pnas.95.26.15665.
K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. Brangi, L. Greenberger, M. Dean, T. Fojo, and S. E. Bates. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8–13 (1999).
M. Maliepaard, M. A. van Gastelen, L. A. de Jong, D. Pluim, R. C. van Waardenburg, M. C. Ruevekamp-Helmers, B. G. Floot, and J. H. Schellens. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:4559–4563 (1999).
D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. Cole, and L. A. Doyle. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91:429–433 (1999). doi:10.1093/jnci/91.5.429.
M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946 (1999).
S. Kawabata, M. Oka, K. Shiozawa, K. Tsukamoto, K. Nakatomi, H. Soda, M. Fukuda, Y. Ikegami, K. Sugahara, Y. Yamada, S. Kamihira, L. A. Doyle, D. D. Ross, and S. Kohno. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 280:1216–1223 (2001). doi:10.1006/bbrc.2001.4267.
S. Koshiba, R. An, H. Saito, K. Wakabayashi, A. Tamura, and T. Ishikawa. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 38:863–888(2008).
P. Krishnamurthy, T. Xie, and J. D. Schuetz. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 114:345–358 (2007). doi:10.1016/j.pharmthera.2007.02.001.
K. Wakabayashi, A. Tamura, H. Saito, Y. Onishi, and T. Ishikawa. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev. 38:371–391 (2006). doi:10.1080/03602530600727947.
P. Rousselot, J. Larghero, E. Raffoux, F. Calvo, M. Tulliez, S. Giraudier, and M. Rybojad. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br. J. Haematol. 120:1091–1092 (2003). doi:10.1046/j.1365-2141.2003.04208_3.x.
V. Brazzelli, F. Prestinari, T. Barbagallo, C. Rona, E. Orlandi, F. Passamonti, F. Locatelli, M. Zecca, S. Villani, and G. Borroni. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J. Eur. Acad. Dermatol. Venereol. 21:384–387 (2007). doi:10.1111/j.1468-3083.2006.01981.x.
C. Ozvegy-Laczka, T. Hegedus, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65:1485–1495 (2004). doi:10.1124/mol.65.6.1485.
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, N. Tsujikawa, S. Tarui, M. Nagakura, M. Osumi, and T. Ishikawa. A new strategy of high-speed screening and quantitative structure–activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther. 317:1114–1124 (2006). doi:10.1124/jpet.105.099036.
J. Dancey, and E. A. Sausville. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2:296–313 (2003). doi:10.1038/nrd1066.
P. M. Nurse. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci. Rep. 22:487–499 (2002). doi:10.1023/A:1022017701871.
P. L. Porter, K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, J. R. Daling, and J. M. Roberts. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222–225 (1997). doi:10.1038/nm0297-222.
J. Tsihlias, L. Kapusta, and J. Slingerland. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50:401–423 (1999). doi:10.1146/annurev.med.50.1.401.
A. Tamura, K. Wakabayashi, Y. Onishi, H. Nakagawa, M. Tsuji, Y. Matsuda, and T. Ishikawa. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. J. Exp. Ther. Oncol. 6:1–11 (2006).
A. Tamura, K. Wakabayashi, Y. Onishi, M. Takeda, Y. Ikegami, S. Sawada, M. Tsuji, Y. Matsuda, and T. Ishikawa. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 98:231–239 (2007). doi:10.1111/j.1349-7006.2006.00371.x.
K. Wakabayashi, H. Nakagawa, A. Tamura, S. Koshiba, K. Hoshijima, M. Komada, and T. Ishikawa. Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J. Biol. Chem. 282:27841–27846 (2007). doi:10.1074/jbc.C700133200.
M. E. Noble, J. A. Endicott, and L. N. Johnson. Protein kinase inhibitors: insights into drug design from structure. Science. 303:1800–1805 (2004). doi:10.1126/science.1095920.
N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, G. Keri, K. Nemet, and B. Sarkadi. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65:1770–1777 (2005). doi:10.1158/0008-5472.CAN-04-3303.
D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65:5399–5407 (2005). doi:10.1158/0008-5472.CAN-05-0233.
H. Saito, H. Hirano, and T. Ishikawa. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini Rev. Med. Chem. 7:1009–1018 (2007). doi:10.2174/138955707782110169.
Acknowledgements
This study was supported, in part, by the NEDO International Joint Research Grant program “International standardization of functional analysis technology for genetic polymorphisms of drug transporters” and research grants (No. 18201041 and No. 19659136) from the Japanese Society for the Promotion of Science (JSPS). Ai Tamura and Hikaru Saito are JSPS Research Fellows.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
An, R., Hagiya, Y., Tamura, A. et al. Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro . Pharm Res 26, 449–458 (2009). https://doi.org/10.1007/s11095-008-9738-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9738-5